Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyra A Gelderman

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|October 14, 2010
In vitro-generated DC with tolerogenic functions: perspectives for in vivo cellular therapyCees van Kooten, Kyra A Gelderman
Expert Opinion on Biological Therapy|December 2, 2005
Inhibiting complement regulators in cancer immunotherapy with bispecific mAbsKyra A Gelderman, Suzanne Lam, Arko Gorter
European Journal of Immunology|March 10, 2006
Cross-linking tumor cells with effector cells via CD55 with a bispecific mAb induces beta-glucan-dependent CR3-dependent cellular cytotoxicityKyra A Gelderman, Suzanne Lam, Cornelis F Sier, et al.
Trends in Immunology|April 10, 2009
The protective role of ROS in autoimmune diseaseMalin Hultqvist, Lina M Olsson, Kyra A Gelderman, et al.
Trends in Immunology|March 24, 2004
Complement function in mAb-mediated cancer immunotherapyKyra A Gelderman, Stephen Tomlinson, Gordon D Ross, et al.
Plos Medicine|September 14, 2006
A new arthritis therapy with oxidative burst inducersMalin Hultqvist, Peter Olofsson, Kyra A Gelderman, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 16, 2006
T cell surface redox levels determine T cell reactivity and arthritis susceptibilityKyra A Gelderman, Malin Hultqvist, Jens Holmberg, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 16, 2002
The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodiesKyra A Gelderman, Vanessa T Blok, Gert Jan Fleuren, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 21, 2007
Lack of reactive oxygen species breaks T cell tolerance to collagen type II and allows development of arthritis in miceMalin Hultqvist, Johan Bäcklund, Kristin Bauer, et al.
Handbook of Experimental Pharmacology|November 26, 2008
Handbook of experimental pharmacology "dendritic cells": the use of dexamethasone in the induction of tolerogenic DCsCees van Kooten, Annelein S Stax, Andrea M Woltman, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Methods in Molecular Biology (Clifton, N.J.)|October 14, 2010
In vitro-generated DC with tolerogenic functions: perspectives for in vivo cellular therapyCees van Kooten, Kyra A Gelderman
Expert Opinion on Biological Therapy|December 2, 2005
Inhibiting complement regulators in cancer immunotherapy with bispecific mAbsKyra A Gelderman, Suzanne Lam, Arko Gorter
European Journal of Immunology|March 10, 2006
Cross-linking tumor cells with effector cells via CD55 with a bispecific mAb induces beta-glucan-dependent CR3-dependent cellular cytotoxicityKyra A Gelderman, Suzanne Lam, Cornelis F Sier, et al.
Trends in Immunology|April 10, 2009
The protective role of ROS in autoimmune diseaseMalin Hultqvist, Lina M Olsson, Kyra A Gelderman, et al.
Trends in Immunology|March 24, 2004
Complement function in mAb-mediated cancer immunotherapyKyra A Gelderman, Stephen Tomlinson, Gordon D Ross, et al.
Plos Medicine|September 14, 2006
A new arthritis therapy with oxidative burst inducersMalin Hultqvist, Peter Olofsson, Kyra A Gelderman, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 16, 2006
T cell surface redox levels determine T cell reactivity and arthritis susceptibilityKyra A Gelderman, Malin Hultqvist, Jens Holmberg, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 16, 2002
The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodiesKyra A Gelderman, Vanessa T Blok, Gert Jan Fleuren, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 21, 2007
Lack of reactive oxygen species breaks T cell tolerance to collagen type II and allows development of arthritis in miceMalin Hultqvist, Johan Bäcklund, Kristin Bauer, et al.
Handbook of Experimental Pharmacology|November 26, 2008
Handbook of experimental pharmacology "dendritic cells": the use of dexamethasone in the induction of tolerogenic DCsCees van Kooten, Annelein S Stax, Andrea M Woltman, et al.
Pageof 5